INDIANAPOLIS – Eli Lilly and Company announced that a statistically significant and clinically significant improvement in overall survival for patients with hormone receptor-positive (HR+), HER2-negative, high-risk early breast cancer has been demonstrated by Verzenio (abemaciclib) when used in conjunction with endocrine therapy. A seven-year study of the Phase 3 monarchE experiment provided the data.
A two-year course of Verzenio combined with endocrine therapy lowers the risk of death compared to endocrine therapy alone, according to the study, which included 5,637 patients from 38 different countries. The drug’s status as a standard of care for this particular patient population, which has a significant risk of cancer recurrence, is supported by this most recent analysis.
Read More: Lilly’s Kisunla (Donanemab) Shows Long-Term Benefit in Treating Early Alzheimer’s Disease
Preventing disease relapse and helping patients live longer is the ultimate goal and a high bar in the adjuvant setting. Achieving a statistically significant OS benefit with just two years of Verzenio therapy reinforces its differentiated profile in high-risk HR+, HER2- early breast cancer,
These data validate Verzenio as the standard-of-care for patients with node-positive, high-risk disease and increase the urgency to ensure all eligible patients are treated.
Jacob Van Naarden
Additionally, the monarchE study demonstrated long-term improvements in distant relapse-free survival and invasive disease-free survival. The most frequent adverse effects were neutropenia and diarrhea, and Verzenio’s safety profile in this long-term follow-up was in line with earlier data.
The most prevalent malignancy among women worldwide is breast cancer. The HR+, HER2-subtype of breast cancer is thought to account for roughly 70% of all cases. Although the prognosis for many of these patients is favorable, those with high-risk characteristics are more likely to experience a recurrence of their cancer, frequently in the form of incurable metastatic disease.
Read More: Trastuzumab: Targeted Therapy for HER2-Positive Cancers – Details, Mechanism, Usage and Side Effects
An oral drug called Verzenio functions by inhibiting particular enzymes known as cyclin-dependent kinases 4 and 6 (CDK4 & 6), which are implicated in the development of cancer cells. Many nations have already licensed it for the treatment of high-risk early breast cancer as well as some forms of advanced or metastatic breast cancer.
Verzenio will be submitted to regulatory bodies for evaluation in light of this promising overall survival data, which is anticipated to further support its usage in the early stages of breast cancer.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
About Verzenio® (abemaciclib)
Cyclin-dependent kinases (CDKs) 4 and 6 are inhibited by verzenio; they become active when they bind to D-cyclins. Cyclin D1 and CDK4 & 6 stimulate retinoblastoma protein (Rb) phosphorylation, cell cycle progression, and cell proliferation in estrogen receptor-positive (ER+) breast cancer cell lines.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
